Related Experiment Videos
Seronegative spondyloarthropathy in familial Mediterranean fever
P Langevitz1, A Livneh, D Zemer
1Heller Institute of Medical Research, Sheba Medical Center, Tel-Hashomer, Israel.
Abstract:
To define a possible association between familial Mediterranean fever (FMF) and seronegative spondyloarthropathy (SNSA) and to study features of SNSA in FMF patients, we screened for the presence and manifestations of SNSA in 3,000 FMF patients attending the National Center for FMF in our institution. This population included 160 patients with chronic arthritis, most who suffered from SNSA. Patients were considered to suffer from SNSA if they had chronic arthritis, inflammatory back/neck pain, and sacroiliitis. Patients who had other diseases associated with SNSA were excluded. Eleven patients, nine men and two women, with chronic monoarthritis or oligoarthritis, grade 2 (four patients) or grades 3 to 4 (seven patients), sacroiliitis, and inflammatory back pain met the criteria for diagnosis of SNSA of FMF. These patients were rheumatoid factor (RF) and HLA-B27 negative. In seven patients, spondyloarthropathy developed while they received colchicine, and in four before colchicine. Most patients responded to treatment with nonsteroidal antiinflammatory drugs, but three required second-line agents. These findings suggest that SNSA is one of the musculoskeletal manifestations of FMF that may occur despite colchicine therapy and requires specific treatment.
Insights
Familial Mediterranean Fever (FMF) is associated with seronegative spondyloarthropathy (SNSA), a musculoskeletal condition. This condition can occur even with FMF treatment and requires specific management.
Area of Science:
- Rheumatology
- Genetics
- Internal Medicine
Background:
- Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disorder.
- Seronegative Spondyloarthropathy (SNSA) encompasses inflammatory joint diseases.
- The association between FMF and SNSA requires further investigation.
Purpose of the Study:
- To determine the association between FMF and SNSA.
- To characterize SNSA manifestations in FMF patients.
- To evaluate treatment outcomes for SNSA in FMF.
Main Methods:
- Screening of 3,000 FMF patients for SNSA.
- Diagnosis of SNSA based on chronic arthritis, inflammatory back/neck pain, and sacroiliitis.
- Exclusion of patients with other known causes of SNSA.
Main Results:
- Eleven FMF patients (9 male, 2 female) met SNSA criteria, exhibiting chronic monoarthritis/oligoarthritis and inflammatory back pain.
- These patients were negative for rheumatoid factor (RF) and HLA-B27.
- SNSA developed during colchicine therapy in 7 patients and before treatment in 4.
Conclusions:
- SNSA is a significant musculoskeletal manifestation in FMF patients.
- SNSA can develop despite ongoing colchicine treatment for FMF.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) were effective, with some patients needing second-line agents for SNSA management.